There are eight subtypes of P2Y receptors (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13
, and P2Y14), which are ubiquitously expressed in body, including the CNS .
A receptor, P2Y13
, mediates the stimulation of the Nrf2/HO-1 axis that leads to neuroprotection.
Also, Cerenis is also pursuing the preclinical development of CER-209, a novel agonist of the P2Y13
receptor for the treatment of atherosclerosis and liver steatosis.
Upon binding of apoA-I, ATP synthase hydrolyzes ATP into ADP and inorganic phosphate, and ADP stimulates hepatic HDL uptake by activating the purinergic receptor P2Y13 through the small GTPase RhoA and its effector ROCK I [28, 36].
Martinez et al., "The nucleotide receptor P2Y13 is a key regulator of hepatic high-density lipoprotein (HDL) endocytosis," Cellular and Molecular Life Sciences, vol.
Eight subtypes of P2Y have been identified to date--P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13
, and P2Y14--with differences in both pharmacology and downstream signalling pathways [3, 4].
There are seven known P2X receptor subtypes (P2X1-7) and eight P2Y receptor subtypes (P2Y1, P2Y2, p2y4, P2Y6, P2Y11, P2Y12, P2Y13
, and P2Y14) .
Champy et al., "Altered lipoprotein metabolism in P2Y13
knockout mice," Biochimica etBiophysica Acta, vol.
At present, there are eight accepted P2Y receptors: P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13
, and P2Y14 [8, 9].